Precision BioSciences Inc (NAS:DTIL)

$ 7.29 0.18 (2.53%) Market Cap: 55.92 Mil Enterprise Value: -14.97 Mil PE Ratio: 121.50 PB Ratio: 0.84 GF Score: 59/100

Precision BioSciences Inc Extraordinary Shareholders Meeting Transcript
Jan 18, 2024
Precision BioSciences Inc at H.C. Wainwright & Co LLC 4th Annual Hepatitis B Virus (HBV) Conference (Virtual) Transcript
Oct 25, 2023
Precision BioSciences Inc at Stifel Tailoring Genes: Genetic Medicines Day (Virtual) Transcript
May 30, 2023
Precision BioSciences Inc Annual Shareholders Meeting Transcript
May 04, 2023
Precision BioSciences Inc at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days (Virtual) Transcript
Apr 03, 2023
Precision BioSciences Inc at HC Wainwright Cell Therapy Virtual Conference Transcript
Feb 28, 2023
Precision BioSciences Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Sep 13, 2022
Precision BioSciences Inc Announces In Vivo Gene Editing Collaboration with Novatris Transcript
Jun 22, 2022
Precision BioSciences Inc Allogeneic CAR T Update- Conference Call Transcript
Jun 08, 2022
Precision BioSciences Inc Annual Shareholders Meeting Transcript
May 10, 2022
Precision BioSciences Inc at Jefferies Gene Therapy/Editing Summit (Virtual) Transcript
Oct 27, 2021
Precision BioSciences Inc PBCAR0191 Clinical Data Call Transcript
Jun 04, 2021
Precision BioSciences Inc Annual Shareholders Meeting Transcript
May 10, 2021
Precision BioSciences Inc Reacquires Global Rights to its Allogeneic CAR T Programs- Conference Call Transcript
Apr 15, 2021
Precision BioSciences Inc at Truist Securities Life Sciences Summit (April Series) Transcript
Apr 13, 2021
Precision BioSciences Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 13, 2021
Cell Gene Meeting on the Mesa - Precision BioSciences Transcript
Jan 08, 2021
Precision BioSciences Inc Interim Data Results for PBCAR0191- Conference Call Transcript
Dec 04, 2020
Precision BioSciences Inc and Eli Lilly and Co In Vivo Gene Editing Collaboration - Conference Call Transcript
Nov 20, 2020

Precision BioSciences Inc Announces In Vivo Gene Editing Collaboration with Novatris Transcript

Jun 22, 2022 / 12:00PM GMT

Release Date Price: $44.7 (+7.19%)

Transcript

Operator

Good day. And thank you for standing by. Welcome to the Precision Biosciences in vivo gene editing collaboration with Novartis. (Operator Instructions). Please be advised that today's conference may be recorded. I would now like to hand the conference over to your speaker today, Alex Kelly, Chief Financial Officer, please go ahead.

Alex Kelly

Chief Financial Officer - Precision Biosciences

Thank you, [Catherine]. And good morning, everyone. And welcome to our webcast to discuss our recently announced in vivo gene editing collaboration with Novartis and the financing that we completed yesterday, which together extend our cash runway to the end of 2024.

Before we begin, I'd like to remind you that the statements we make today on this webcast that do not relate to material -- relate to matters of historical fact, our future expectations, and forward-looking statements.

Our forward looking statements are within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks,

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.